Much better described than I could. We are definately on the same page.
I hold both companies as I see them attacking the cancer problem from far different angles.
CHM proved in the lab they had a kick ass drug that could bind to destroy solid tumor cancer. This is almost the holy grail for CarT.
They picked one of the most agressive solid tumor cancers, which has no effective SOC to start trials. This is a very clever move. As patient life expecancy is not long, with many not surviving past 6 months, they can quickly prove if the drug is effective, or not. As there is an unmet need, the drug approval process can be elligible for fast tracking. This also means more tolerence is given towards saftey.
This is an incredibly high bang for buck developement process. And once approval is gained for GBM it is far easier to spin to off into other indications. If the science works as well as they believe, this will be the drug that keeps on giving.
Now PTX have a bit more of a diverse pipeline. They have a drug targeting AKT and another targetting Kras in the clinic now. Kras is a new kid on the street, and a mono therapy trial showed it works a treat. The AKT drug has given 3 CRs so far in a combination trial. But the method of combination caused some safety issues. That trial had to be redesigned, and a readout is due soon.
CarT wise, they are developing some next gen (new
) cell tech that will be hitting arms next year for a variety of indications. This cell tech looks like it will be used with the spycatcher tech of OmniCar, but details are still under wraps. They will be after both solid tumour and blood cancer.
The CarT space in blood cancers is becoming a bit over crowded. So CHM starting their first trial in solid tumor is clever. However, as I stated before OmniCar is backward compatible. So an early approved CarT in the blood cancer space may be keen to increase market share by using OmniCar tech to next gen their older drug. Recent lab tests seem to support Omnicar will not only make them safer, but help them work better (better binding) and longer (be able to turn them on and off). But, until a deal is done that all just pie in the sky stuff.
The ASX has some very clever drug discovery Biotechs on board. The tax rebate system is a big attraction getter for this.
